SecBot SecBot
SECBOTREPLAY Home › Report › DNTH

DNTH · Dianthus Therapeutics CEO, R&D head, and CFO-equivalent executed a…

Dianthus Therapeutics, Inc. /DE/ · CLUSTER filed Mar 11, 2026 at 20:00 ET

At the news

BEARISHIMPACT 7/10

CLUSTER filed Mar 11, 2026 at 20:00 ET

Dianthus Therapeutics CEO, R&D head, and CFO-equivalent executed a coordinated cluster of derivative exercises and open-market sales over a 7-day window, realizing $7.5M in proceeds. The transactions include both non-cash exercises and direct sales at prices between $80.70 and $81.48, with the CEO and CFO selling over $4.7M and $1.2M respectively.

  • CEO Garcia Marino sold $3.51M in shares and exercised derivatives for 182,618 shares (partially non-cash), realizing $1.22M in cost basis.
  • EVP Randhawa Simrat sold $2.76M and exercised derivatives for 15,996 shares with $67,503 in cost basis.
  • Chief Accounting Officer Carr sold $1.28M and exercised 16,182 shares with $289,334 in cost basis.
  • Total open-market sales: $7.5M across 3 insiders on March 12, coinciding with peak stock price activity.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access